Please ensure Javascript is enabled for purposes of website accessibility

This Genetics Stock Could Have a Bright Future

By Matthew Frankel, CFP® and Brian Orelli, PhD - Updated Jun 23, 2021 at 8:29AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's one genetics play that you might want to put on your radar.

There's no doubt that the genetics industry is full of investment opportunities. In this Fool Live video clip, recorded on May 21, Fool.com contributor Brian Orelli, PhD, and healthcare bureau chief Corinne Cardina discuss why Intellia Therapeutics (NTLA 1.00%) should be on investors' radar. 

Corinne Cardina: All right, so Intellia, in the clinic, has an in vivo program. It is called, let's see if I can say this, transthyretin amyloidosis, it is shortened as ATTR. This is caused by the accumulation of misfolded protein, and that's what TTR is, that's the protein. The disease affects your nerves, your heart, your kidneys, and your eyes. There is a current treatment, but it requires chronic dosing. Of course, as with most of these in vivo programs, it has the potential to be a one-and-done dose, cure with one. Again, we're going to talk more about partnerships later on, but this particular program is in partnership with Regeneron (REGN 2.32%). They also are testing in the clinic in ex vivo program for sickle cell, and that is in partnership with Novartis (NVS -0.35%). Further out, Intellia is also testing an in vivo program for hereditary angioedema, which is the swelling. They're also testing hemophilia A and B in vivo. Then ex vivo, they are testing acute myeloid leukemia as well as solid tumors. They are also looking at immuno-oncology, although of course these are much earlier on than their in-the-clinic programs. The ATTR market for that main in vivo candidate. There are 50,000 patients who have the hATTR indication.

Brian Orelli: H is for hereditary.

Cardina: Thank you. What is wATTR, Brian?

Orelli: I'm not actually sure what wA is, but it happens spontaneously. Presumably, the other that's more common is that it happens spontaneously.

Cardina: Okay.

Orelli: Tends to be in older patients, but I don't actually know what wA is.

Cardina: I got this from the company site, 200,000 to 500,000, which tracks what they're saying much more common wATTR patients, and that is a worldwide market. It's very interesting, it's not a disease that I have really heard of before, but Brian, did you have anything to add on the indications Intellia's targeting?

Orelli: No. There are a couple of treatments for ATTR. Pfizer (PFE -0.72%) has one and then so does Alnylam (ALNY -1.21%) and Honest Pharmaceuticals all have treatments. Then it comes in two forms, so it comes in a narrow form, where the TTR protein tends to barge into the nerve cells and that causes those neurological side effects. Then it also comes in the heart form, where it lodges in the heart and then that causes problems with heart. Some people have both types of symptoms.

Brian Orelli, PhD has no position in any of the stocks mentioned. Corinne Cardina has no position in any of the stocks mentioned. Matthew Frankel, CFP has no position in any of the stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intellia Therapeutics Stock Quote
Intellia Therapeutics
NTLA
$68.42 (1.00%) $0.68
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.75 (-0.72%) $0.36
Novartis AG Stock Quote
Novartis AG
NVS
$85.38 (-0.35%) $0.30
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$643.29 (2.32%) $14.58
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$231.01 (-1.21%) $-2.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.